Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzalutamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution form
Details : Bdenza (enzalutamide) is a small molecule AR inhibitor available in oral solution form, which is approved for the treatment of patients with prostate cancer.
Product Name : Bdenza
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apalutamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharmaceutical Launches Generic Drug for Treating Prostate Cancer in India
Details : APATIDE (generic version of Apalutamide) is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain and blocks AR nuclear translocation or binding to androgen response elements. Product has been launched in India to...
Product Name : Apatide
Product Type : HPAPI
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Apalutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Biapenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDR Pharma elevates its own standard of the wide range of critical care segment products with launch of biapenem under brand name Biapen to treat intra-abdominal, lower respiratory or complicated urinary tract infections, which will be available in the m...
Product Name : Biapen
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : Biapenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharma Launches Cabozantinib to Treat Metastatic Medullary Thyroid Cancer
Details : Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer (MTC) and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Inapplicable
September 14, 2021
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baricitinib,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Mankind Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Mankind Pharma Inks Distribution Pact with BDR Pharmaceuticals for COVID Drug
Details : Under the partnership, BDR Pharma will be manufacturing & marketing Barikind (baricitinib) which received restricted emergency use approval for use in combination with remdesivir for treating COVID19.
Product Name : Barikind
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2021
Lead Product(s) : Baricitinib,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Mankind Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Rucaparib Camsylate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3. BDPARIB is first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the m...
Product Name : Bdparib
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2021
Lead Product(s) : Rucaparib Camsylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenvatinib Mesylate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharma Launches Generic Lenvatinib for Cancer Patients in India
Details : Bdfoie (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Product Name : Bdfoie
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2020
Lead Product(s) : Lenvatinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharmaceuticals Launches Favipiravir Under Brand name 'BDFAVI' at Rs 63 per Tablet in India
Details : BDR pharma has received an approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat mild to moderate patients with COVID-19 symptoms. The drug has been launched under the brand name 'BDFAVI.
Product Name : Bdfavi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable